Open AccessThe effect of metabolic syndrome on prostate cancer final pathology
Author(s) -
Selahattin Çalışkan,
Selçuk Kaba,
Emrah Özsoy,
Muzaffer Oğuz Keleş,
Orhan Koca,
Mehmet Akyüz,
Muhammet İhsan Karaman
Publication year - 2019
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.187290
Subject(s) - medicine , metabolic syndrome , prostate cancer , diabetes mellitus , incidence (geometry) , disease , cancer , prostate , gastroenterology , obesity , endocrinology , physics , optics
Metabolic syndrome (MetS) is an abnormality that increases the risk of cardiovascular disease and diabetes. In the recent years, studies showed that MetS is associated with increased risk of incidence, aggressiveness, and mortality of prostate cancer (PCa). We examined the influence of MetS at final pathology in Turkish patients with PCa.